Meeting
2019 ASCO Annual Meeting
Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.
Authors
Yaw A. Nyame
Department of Urology, University of Washington Medical Center, Seattle, WA
Yaw A. Nyame , Sarah K Holt , Brian Winters , Sarah P. Psutka , Atreya Dash , George R Schade , Daniel W. Lin , Leonidas Nikolaos Diamantopoulos , Petros Grivas , Evan Y. Yu , John L. Gore , Jonathan L. Wright
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4532)
DOI
10.1200/JCO.2019.37.15_suppl.4532
Abstract #
4532
Poster Bd #
358
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron
Poster
2013 ASCO Annual Meeting
Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209.
First Author: Hiroshi Kitamura
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman